Cargando…

Central nervous system disease in phase III studies for advanced HER2 positive breast cancer: A review

IMPORTANCE: The introduction of human epidermal growth factor receptor 2 (HER2) directed therapy has transformed the outcomes of patients with advanced breast cancer (BC). However, HER2 positive breast cancer has a predilection for the central nervous system (CNS) which is associated with significan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bhogal, Talvinder, Cameron, David, Palmieri, Carlo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961215/ https://www.ncbi.nlm.nih.gov/pubmed/35344688 http://dx.doi.org/10.1016/j.breast.2022.03.013

Ejemplares similares

Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA
por: Swain, S. M., et al.
Publicado: (2014)

Lapatinib Plus Capecitabine in Women with HER-2–Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial
por: Cameron, David, et al.
Publicado: (2010)

Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial
por: Pérez-García, José Manuel, et al.
Publicado: (2022)

SDPS-46 CENTRAL NERVOUS SYSTEM (CNS)-RELATED MORTALITY IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER
por: Ferraro, Emanuela, et al.
Publicado: (2023)

Pertuzumab retreatment for HER2‐positive advanced breast cancer: A randomized, open‐label phase III study (PRECIOUS)
por: Yamamoto, Yutaka, et al.
Publicado: (2022)

Advances in the Management of Central Nervous System Metastases from Breast Cancer
por: Avila, Jorge, et al.
Publicado: (2022)

Safety and efficacy of the combination of T-DM1 with radiotherapy of the central nervous system in a patient with HER2-positive metastatic breast cancer: case study and review of the literature
por: Borges, Giuliano Santos, et al.
Publicado: (2015)

Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status
por: Souglakos, John, et al.
Publicado: (2006)

Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer
por: Morrow, Phuong Khanh H, et al.
Publicado: (2009)

Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
por: Stanowicka-Grada, Malwina, et al.
Publicado: (2023)

Corrections to “Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer”
por: Baselga, J., et al.
Publicado: (2019)

Advances in the Physiology of GPR55 in the Central Nervous System
por: Marichal-Cancinoa, Bruno A., et al.
Publicado: (2017)

Advances in Pathobiology of Primary Central Nervous System Lymphoma
por: Yang, Xue-Liang, et al.
Publicado: (2017)

Advances in Optogenetics Applications for Central Nervous System Injuries
por: Geng, Yuanming, et al.
Publicado: (2023)

Editorial: Advance in diagnostics for central nervous system infection
por: Abu-Rumeileh, Samir, et al.
Publicado: (2023)

Advances in neoadjuvant therapy for HER2-positive breast cancers: a narrative review
por: Wang, Qianmu, et al.
Publicado: (2022)

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
por: Barrios, Carlos H., et al.
Publicado: (2010)

Treatment patterns, clinical outcomes and health care costs associated with her2-positive breast cancer with central nervous system metastases: a French multicentre observational study
por: Baffert, Sandrine, et al.
Publicado: (2013)

A review on recent advances on nobiletin in central and peripheral nervous system diseases
por: Pang, Yueshan, et al.
Publicado: (2023)

Antiviral Type I and Type III Interferon Responses in the Central Nervous System
por: Sorgeloos, Frédéric, et al.
Publicado: (2013)

Methionine adenosyltransferase I/III deficiency: beyond the central nervous system manifestations
por: Nashabat, Marwan, et al.
Publicado: (2018)

The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial
por: Jaeger, B. A. S., et al.
Publicado: (2017)

New Agents for the Management of Advanced HER2-Positive Breast Cancer
por: Royce, Melanie, et al.
Publicado: (2016)

Targeting HER2-positive breast cancer: advances and future directions
por: Swain, Sandra M., et al.
Publicado: (2022)

Pyrotinib for Elderly Patients with Advanced HER2-Positive Breast Cancer
por: Li, Yan, et al.
Publicado: (2022)

Advancing the Care of Women With HER2-Positive Metastatic Breast Cancer
por: Beasley, Marcie, et al.
Publicado: (2023)

Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial
por: Yang, Yang, et al.
Publicado: (2023)

Recent Advances in the Developmental Biology of Central Nervous System Malformations
por: Noebels, Jeffrey L.
Publicado: (1980)

Advances in Neurology: Vol. 15. Neoplasia in the Central Nervous System
por: Yates, P. O.
Publicado: (1976)

Recent Advances in Treatment of Primary Central Nervous System Lymphoma
por: Nayak, Lakshmi, et al.
Publicado: (2013)

Recent advances in the management of primary central nervous system lymphoma
por: Choi, Yoon Seok
Publicado: (2020)

Recent Advances on Extracellular Vesicles in Central Nervous System Diseases
por: Jin, Tao, et al.
Publicado: (2021)

Relapsed Primary Central Nervous System Lymphoma: Current Advances
por: Tao, Kaiyan, et al.
Publicado: (2021)

Editorial: Advances in the treatment of primary central nervous system lymphoma
por: Qian, Liren, et al.
Publicado: (2023)

Dalpiciclib and pyrotinib in women with HER2-positive advanced breast cancer: a single-arm phase II trial
por: Yan, Min, et al.
Publicado: (2023)

Recent Advances in Systemic Treatments for HER-2 Positive Advanced Gastric Cancer
por: Kahraman, Seda, et al.
Publicado: (2021)

Advances and Opportunities in Nanoparticle Drug Delivery for Central Nervous System Disorders: A Review of Current Advances
por: Ekhator, Chukwuyem, et al.
Publicado: (2023)

The Central Nervous System
por: De Lorenzi, Davide, et al.
Publicado: (2016)

The Central Nervous System
por: De Lorenzi, Davide, et al.
Publicado: (2010)

Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer
por: Perez, Edith A., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_i1lsj1n0l29j0qr1sqj3269j8l